Latest Product Development News

Spenda Limited has secured $1.85 million from its institutional entitlement offer at $0.004 per share, progressing its $8.545 million capital raise aimed at debt reduction and product development. The retail component opens next week to raise an additional $6.7 million.

Spenda Limited (ASX:SPX) has kicked off an $8.545 million accelerated entitlement offer at a steep discount, aiming to strengthen its balance sheet, reduce debt, and support its strategic reset towards profitability.

Greenvale Energy has completed initial product assessments for its Alpha Project bitumen samples, successfully separating volatile fractions and producing a bitumen-like material. The company plans further processing to meet industry specifications and awaits independent certification.

VEEM Limited has finished its factory extension and installed new machinery, setting the stage for a stronger second half of FY26 and anticipated growth in FY27 driven by defence contracts and marine propulsion innovations.

ArborGen Holdings announces CEO Justin Birch's resignation after three years, appointing Patrick Cumbie as interim CEO while searching for a permanent replacement.

Treasury Wine Estates (ASX:TWE) unveils its Ascent transformation, targeting $100 million annual savings, portfolio focus on Power Brands, and a leaner supply chain to lift margins and reduce leverage by FY28.

Biome Australia has inked a binding deal with Specialty Probiotics Australia to shift its Activated Probiotics manufacturing onshore, aiming to boost gross margins above 65% and streamline working capital within 18 months.

Swift TV has completed a multi-year Google certification process for its enterprise connected TV platform, validating its technology and supporting ongoing deployments across mining, aged care, and hospitality sectors.

Simble Solutions has launched a strategic collaboration with Macquarie University to accelerate development of its exclusive zinc oxide nanosensor technology, targeting e-skin applications and integration into its IoT platforms.

QuickFee Limited has reported a robust 77% increase in Australian originations for Q4 FY26 to-date, driven by strong Fee Funding and Disbursement Funding growth. The company boosted its Australian credit facility by A$15 million, signalling confidence in its low-risk lending model, while US operations focus on reseller channel expansion amid a product embedding delay.

ReadyTech Holdings has dismissed an unsolicited acquisition proposal valuing the company at $2.00 per share, calling it undervalued and unworkable. The offer includes a parallel off-market bid at $1.75 per share with a 50.1% minimum acceptance condition.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.